JP2019088286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019088286A5 JP2019088286A5 JP2018243703A JP2018243703A JP2019088286A5 JP 2019088286 A5 JP2019088286 A5 JP 2019088286A5 JP 2018243703 A JP2018243703 A JP 2018243703A JP 2018243703 A JP2018243703 A JP 2018243703A JP 2019088286 A5 JP2019088286 A5 JP 2019088286A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ala
- seq
- ile
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020114090A JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701056P | 2012-09-14 | 2012-09-14 | |
| US61/701,056 | 2012-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Division JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114090A Division JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019088286A JP2019088286A (ja) | 2019-06-13 |
| JP2019088286A5 true JP2019088286A5 (https=) | 2019-10-24 |
| JP6728326B2 JP6728326B2 (ja) | 2020-07-22 |
Family
ID=49253425
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Active JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2018243703A Active JP6728326B2 (ja) | 2012-09-14 | 2018-12-26 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Active JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9879065B2 (https=) |
| EP (3) | EP4159753A1 (https=) |
| JP (4) | JP6461796B2 (https=) |
| KR (4) | KR102303166B1 (https=) |
| CN (2) | CN104968675B (https=) |
| AU (4) | AU2013315391B2 (https=) |
| CA (1) | CA2884743C (https=) |
| CY (1) | CY1122720T1 (https=) |
| DK (2) | DK2895509T3 (https=) |
| ES (2) | ES2774931T3 (https=) |
| HR (1) | HRP20200325T1 (https=) |
| HU (1) | HUE048014T2 (https=) |
| IL (3) | IL286786B (https=) |
| LT (1) | LT2895509T (https=) |
| MX (2) | MX367279B (https=) |
| PL (1) | PL2895509T3 (https=) |
| PT (1) | PT2895509T (https=) |
| SI (1) | SI2895509T1 (https=) |
| SM (1) | SMT202000103T1 (https=) |
| WO (1) | WO2014043441A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286786B (en) * | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| US10973894B2 (en) | 2014-10-02 | 2021-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
| ES2983924T3 (es) * | 2015-03-27 | 2024-10-28 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| WO2017142988A1 (en) | 2016-02-18 | 2017-08-24 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| PL3430037T3 (pl) * | 2016-03-16 | 2022-12-19 | Immatics Biotechnologies Gmbh | Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| WO2018097951A1 (en) | 2016-11-22 | 2018-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3/a6 antibodies |
| DE102016123859B3 (de) * | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| CN108250289B (zh) * | 2016-12-28 | 2021-10-08 | 香雪生命科学技术（广东）有限公司 | 源自于mage b6的肿瘤抗原短肽 |
| JP7348063B2 (ja) | 2017-01-05 | 2023-09-20 | フレッド ハッチンソン キャンサー センター | ワクチン効力を改善するためのシステム及び方法 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| AU2018345400B2 (en) * | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| WO2019075055A1 (en) | 2017-10-11 | 2019-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| CN109837248A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用 |
| CN109836490A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用 |
| CN111629715A (zh) | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| EP3749770B9 (en) | 2018-02-09 | 2025-12-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Tethered interleukin-15 and interleukin-21 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CN112236447B (zh) * | 2018-04-19 | 2023-10-20 | 得克萨斯州大学系统董事会 | 具有mage-b2特异性的t细胞受体及其用途 |
| US12415845B2 (en) | 2018-04-24 | 2025-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| KR20220030933A (ko) | 2019-05-08 | 2022-03-11 | 메디진 이뮤노테라피스 게엠바하 | 조작된 t 세포 |
| MX2022000667A (es) * | 2019-07-15 | 2022-07-21 | Neogene Therapeutics B V | Metodo para aislar genes tcr. |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| WO2022055946A1 (en) | 2020-09-08 | 2022-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| WO2023130040A2 (en) | 2021-12-31 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EA201390011A1 (ru) * | 2010-07-28 | 2013-07-30 | Иммьюнокор Лтд. | Т-клеточные рецепторы |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
| ES2834070T3 (es) | 2011-09-15 | 2021-06-16 | Us Health | Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7 |
| US9413985B2 (en) * | 2012-09-12 | 2016-08-09 | Lattice Semiconductor Corporation | Combining video and audio streams utilizing pixel repetition bandwidth |
| IL286786B (en) * | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
-
2013
- 2013-09-13 IL IL286786A patent/IL286786B/en unknown
- 2013-09-13 AU AU2013315391A patent/AU2013315391B2/en active Active
- 2013-09-13 KR KR1020207028713A patent/KR102303166B1/ko active Active
- 2013-09-13 SM SM20200103T patent/SMT202000103T1/it unknown
- 2013-09-13 EP EP22174521.9A patent/EP4159753A1/en active Pending
- 2013-09-13 ES ES13767200T patent/ES2774931T3/es active Active
- 2013-09-13 LT LTEP13767200.2T patent/LT2895509T/lt unknown
- 2013-09-13 US US14/427,671 patent/US9879065B2/en active Active
- 2013-09-13 KR KR1020227006700A patent/KR102480188B1/ko active Active
- 2013-09-13 EP EP13767200.2A patent/EP2895509B1/en active Active
- 2013-09-13 CN CN201380059102.4A patent/CN104968675B/zh active Active
- 2013-09-13 DK DK13767200.2T patent/DK2895509T3/da active
- 2013-09-13 PL PL13767200T patent/PL2895509T3/pl unknown
- 2013-09-13 HU HUE13767200A patent/HUE048014T2/hu unknown
- 2013-09-13 MX MX2015003061A patent/MX367279B/es active IP Right Grant
- 2013-09-13 EP EP19212016.0A patent/EP3636665B1/en active Active
- 2013-09-13 KR KR1020217029207A patent/KR102370307B1/ko active Active
- 2013-09-13 SI SI201331678T patent/SI2895509T1/sl unknown
- 2013-09-13 PT PT137672002T patent/PT2895509T/pt unknown
- 2013-09-13 WO PCT/US2013/059608 patent/WO2014043441A1/en not_active Ceased
- 2013-09-13 KR KR1020157006543A patent/KR102165350B1/ko active Active
- 2013-09-13 CN CN202111028896.0A patent/CN113754755A/zh active Pending
- 2013-09-13 JP JP2015532065A patent/JP6461796B2/ja active Active
- 2013-09-13 CA CA2884743A patent/CA2884743C/en active Active
- 2013-09-13 HR HRP20200325TT patent/HRP20200325T1/hr unknown
- 2013-09-13 DK DK19212016.0T patent/DK3636665T3/da active
- 2013-09-13 ES ES19212016T patent/ES2925307T3/es active Active
-
2015
- 2015-03-04 IL IL237560A patent/IL237560B/en active IP Right Grant
- 2015-03-10 MX MX2019009641A patent/MX2019009641A/es unknown
-
2017
- 2017-08-23 AU AU2017219019A patent/AU2017219019B2/en active Active
- 2017-12-20 US US15/848,344 patent/US10611815B2/en active Active
-
2018
- 2018-12-26 JP JP2018243703A patent/JP6728326B2/ja active Active
-
2019
- 2019-08-06 AU AU2019213329A patent/AU2019213329B2/en active Active
-
2020
- 2020-03-03 CY CY20201100190T patent/CY1122720T1/el unknown
- 2020-03-09 US US16/812,845 patent/US20200270329A1/en not_active Abandoned
- 2020-04-16 IL IL274003A patent/IL274003B/en unknown
- 2020-07-01 JP JP2020114090A patent/JP6923714B2/ja active Active
-
2021
- 2021-06-07 AU AU2021203746A patent/AU2021203746B2/en active Active
- 2021-07-29 JP JP2021124003A patent/JP7270001B2/ja active Active
-
2022
- 2022-09-28 US US17/936,006 patent/US12404317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019088286A5 (https=) | ||
| JP2019528061A5 (https=) | ||
| Liu et al. | Targeting cadherin‐17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma | |
| ES2784237T3 (es) | Receptores de células T anti-papilomavirus 16 E7 humano | |
| JP2026021299A5 (https=) | ||
| Yoo et al. | Oncolytic virus‐based immunotherapies for hepatocellular carcinoma | |
| CN113382745A (zh) | 用DuoCAR治疗癌症的组合物和方法 | |
| JP2018536431A5 (https=) | ||
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| CN108473950A (zh) | 靶向癌症治疗 | |
| JP2017186337A5 (https=) | ||
| CN102459344A (zh) | 抗axl抗体 | |
| JP2020521478A5 (https=) | ||
| WO2019158955A1 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2024122983A (ja) | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス | |
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| US20220267770A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| WO2016127873A1 (zh) | 异硫氰酸酯类化合物及其应用 | |
| JP2020511139A5 (https=) | ||
| Fallah et al. | A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment | |
| JP2017515806A5 (https=) | ||
| Ooi et al. | RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update | |
| JP2020526202A5 (https=) | ||
| CN113577093A (zh) | 一种治疗结直肠癌的药物 | |
| JP2011162466A (ja) | 新規クローディン結合分子およびその利用 |